Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CRCL-AlloVax in advanced hepatocellular carcinoma
NCT02409524Phase 2Completed
- Sponsor
- Mirror Biologics, Inc.
- Start
- Jul 2016
- Primary completion
- Jun 2017
- Modality
- Cell Therapies, Cancer Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of AlloVax in hepatocellular carcinoma (HCC), sponsored by Mirror Biologics, Inc.. Started Jul 2016; status: completed.
02
Drugs
AlloVax
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT02409524.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02409524.